TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
AstraZeneca reported positive Phase 3 SAFFRON results showing TAGRISSO plus savolitinib cut the risk of disease progression or death by 45% and the risk of death by 32% versus chemotherapy in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO. Median overall survival was extended by 4.9 months (17.8 vs 12.9 months), with median PFS of 7.6 vs 5.4 months; results were presented at the ESMO Presidential Symposium and published in the New England Journal of Medicine.
Key figures
- Drug Name
- TAGRISSO (osimertinib) plus savolitinib
- Phase Of Trial
- Phase 3
- Countries
- 29
- Nda submitted
- Yes
- Os hazard ratio
- 0.68
- Median os months
- 17.8 vs 12.9
- Pfs hazard ratio
- 0.55
- Trial enrollment
- 338
- Median pfs months
- 7.6 vs 5.4 (combination vs chemotherapy)
- Os risk reduction
- 32%
- Pfs risk reduction
- 45%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.